Kelley Bernheim Dolinsky, LLC Warns Dialysis Patients About

Kelley Bernheim Dolinsky, LLC Warns Dialysis Patients About Heart
Attack Risks Associated With Recall of Fresenius Medical Care's
Dialysis Drugs 
BOSTON, MA -- (Marketwire) -- 08/15/12 --   Kelley Bernheim Dolinsky,
LLC, national consumer safety law firm specializing in product
liability litigation -- www.duejustice.com -- is alerting dialysis
patients of the FDA's Class I Recall -- the most serious -- for
dialysis drugs GranuFlo and NaturaLyte manufactured by Fresenius
Medical Care, headquartered in Waltham, Massachusetts. 
Walter Kelley, managing attorney at Kelley Bernheim Dolinsky, LLC's
Boston office, explained, "Fresenius' GranuFlo dialysis products are
the subject of a Class I recall by the FDA, following discovery in
2010 that more than 900 patients suffered cardiac arrest at Fresenius
dialysis clinics. GranuFlo contains elevated bicarbonate levels,
considered a major risk factor in cardiac arrest. Sadly, we believe
top Fresenius executives may have known of this potential problem in
2003. Even worse, when a clinical problem became evident in 2010, it
appears they didn't take appropriate measures to warn the FDA or any
government agency." 
From ongoing coverage in the New York Times, Fresenius is being
investigated for failing to warn customers about serious risks
associated with GranuFlo and NaturaLyte. Fresenius had issued an
internal memo to its own clinics on November 4, 2011, warning that
941 hemodialysis patients experienced cardiac arrest at 667 Fresenius
facilities in 2010. The company's analysis of these patients,
comparing them to over 80,000 dialysis patients in the same centers,
indicated excess bicarbonate, or alkalosis, significantly increased
risk of heart problems in hemodialysis patients. 
Attorney Kelley added, "While Fresenius alerted its own physicians
and medical directors about the issue, it did not notify the general
public, the FDA or other clinics using their dialysis products until
the agency received an anonymous copy of the memo. Subsequently, the
FDA issued a Safety Communication warning about potential dosing
errors for products like GranuFlo and NaturaLyte in hemodialysis
patients." 
"If there was collusion to mislead and obscure information about
patients' safety hazards, that is despicable," Attorney Kelley
continued. "Putting patients at risk in order to maintain a market
share or to minimize legal responsibility would justify a
Massachusetts Court to impose punitive damages against Fresenius if
the evidence is there," he said. 
For more information about Fresenius dialysis heart attack claims and
settlements, contact Kelley Bernheim Dolinsky, LLC at (888) 554-2889
or www.duejustice.com 
For further information contact:
Steven Swartz
McDougall Interactive
978-750-8000 ext. 18
ss@mcdia.com 
 
 
Press spacebar to pause and continue. Press esc to stop.